CLINICAL_TRIALS
trial_result
· 2019-01-07
Clinical Trial Update: A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura [Phase 3]
Summary
Phase 3 safety study of galcanezumab in migraine patients with or without aura has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2019-01-07